Biocon

Biocon

354.35
-5.85
(-1.62%)
Market Cap
48,157.40 Cr
EPS
8.46
PE Ratio
133.74
Dividend Yield
0.13 %
Industry
Healthcare
52 Week High
406.00
52 Week Low
291.00
PB Ratio
1.81
Debt to Equity
0.84
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+62.50 %
+62.50 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+18.75 %
+18.75 %

Company News

View All News
Caret
neutral
Biocon Limited has set September 18, 2025 as the record date for the buyback of its listed Commercial Paper with ISIN INE376G14032. The buyback is scheduled for September 19, 2025. The Commercial Paper has an issue size of Rs. 600 crore and is listed on the National Stock Exchange of India Limited. The company communicated this information to both NSE and BSE through a formal letter dated September 17, 2025.
positive
Biocon Biologics received U.S. FDA approval for Bosaya and Aukelso, biosimilars of Prolia and Xgeva respectively. Both products received provisional interchangeability designation from the FDA. Bosaya is approved for treating osteoporosis in various patient populations, while Aukelso is approved for preventing skeletal-related events in cancer patients and treating giant cell tumor of bone. According to IQVIA data, denosumab had nearly $5 billion in U.S. sales for the period ended December 2024. Shreehas Tambe, CEO of Biocon Biologics, stated this approval expands access to more affordable biologic therapies and reinforces the company's commitment to delivering high-quality biosimilars. Clinical data showed both biosimilars demonstrated comparable quality, safety, and efficacy to the reference products.
positive
Biocon will file applications to launch generic versions of Ozempic in multiple markets during the current quarter. CEO Siddharth Mittal expects entry into emerging markets by end-2026, with US launch planned for early 2026. The company already sells Liraglutide API for GLP-1 drugs in the UK and Europe. Semaglutide patents expire in 2031 in the US and Europe. Biocon joins at least 15 companies competing for the global GLP-1 opportunity estimated at over $160 billion by 2034. The company has developed processes to compete with Chinese API sources, and its Bengaluru plant may start generating revenues within 2-3 years.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,620.20
#1 3,86,412.90
33.89
#1 54,729.00
9.71
#1 10,980
-19.84
49.41
6,051.50
1,61,922.60
69.65
9,712.00
18.67
2,191
26.74
46.47
1,559.60
1,25,921.60
23.36
28,409.50
7.12
5,291
9.88
51.03
3,548.30
1,19,657.40
59.39
11,539.40
6.99
1,911
19.91
42.91
1,311.40
1,09,362.20
#1 19.26
33,741.20
16.73
5,725
1.26
60.11
2,570.20
1,06,063.00
56.09
12,744.20
#1 20.90
2,007
-18.14
53.12
1,033.80
1,04,094.90
22.34
23,511.00
18.55
4,615
2.60
62.88
2,031.20
93,704.80
25.08
22,909.50
13.74
3,306
#1 51.64
68.18
5,472.50
65,796.60
28.79
13,458.30
3.70
2,216
21.39
70.33
30,970.00
65,724.10
45.28
6,684.70
9.64
1,414
11.55
39.16
Forecast
Actual
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
952
778
800
811
1,223
1,029
989
1,086
974
986
1,025
1,098
1,242
1,193
1,564
1,585
1,557
1,483
1,673
1,784
1,621
1,712
1,765
1,885
2,060
1,808
1,945
2,223
2,476
2,217
2,384
3,020
3,929
3,516
3,551
4,135
3,912
4,543
3,604
3,826
4,415
3,990
Expenses
653
606
727
615
740
719
706
762
738
735
786
836
937
886
982
1,160
1,137
1,029
1,174
1,307
1,247
1,284
1,363
1,459
1,476
1,427
1,515
1,733
1,911
1,783
1,894
2,624
2,820
2,741
2,769
3,051
3,013
2,813
2,905
3,070
3,339
3,193
EBITDA
300
172
73
196
483
309
283
324
236
250
239
262
306
307
582
425
420
454
499
477
373
428
402
427
584
380
430
489
565
434
490
396
1,109
775
782
1,084
900
1,730
699
756
1,077
797
Operating Profit %
21 %
20 %
6 %
22 %
21 %
27 %
25 %
27 %
20 %
21 %
19 %
21 %
20 %
21 %
26 %
25 %
26 %
29 %
25 %
25 %
20 %
24 %
22 %
21 %
20 %
19 %
18 %
20 %
21 %
17 %
18 %
11 %
25 %
20 %
18 %
14 %
22 %
17 %
18 %
19 %
23 %
18 %
Depreciation
59
59
61
64
65
66
68
70
73
99
94
97
95
99
112
117
120
124
132
144
152
167
178
186
184
195
202
206
212
218
231
301
364
358
389
415
407
405
420
425
436
455
Interest
0
4
3
2
21
6
7
9
5
16
14
15
17
18
19
19
16
17
14
18
17
13
7
5
34
20
23
15
11
20
30
120
249
233
248
267
227
236
226
223
212
277
Profit Before Tax
249
165
20
141
409
238
208
245
159
135
132
150
193
190
451
289
284
313
354
315
204
249
218
236
366
166
206
269
343
197
229
-26
497
184
214
808
319
1,146
98
156
487
97
Tax
32
34
18
19
55
55
42
54
10
38
43
36
41
52
73
46
41
85
100
85
45
81
22
49
69
57
46
49
59
30
147
-5
82
35
42
55
96
284
71
75
27
8
Net Profit
217
131
2
122
354
182
167
191
148
98
89
114
153
138
378
243
243
228
254
230
159
168
195
187
296
108
160
220
284
167
82
-21
415
149
173
753
223
862
27
81
459
89
EPS in ₹
10.08
6.31
-0.54
5.30
16.97
8.49
7.48
8.72
6.49
1.38
1.17
1.56
2.21
1.02
3.00
3.67
3.61
1.74
1.82
1.71
1.04
1.26
1.39
1.42
2.13
0.71
1.16
1.57
2.00
1.21
0.39
-0.35
2.62
0.85
1.05
5.52
1.13
5.51
-0.13
0.21
2.88
0.26

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
58,797
Fixed Assets
1,630
1,749
3,626
3,700
4,471
5,971
6,364
6,569
29,468
30,644
31,963
Current Assets
2,563
3,971
4,048
4,149
4,889
5,325
7,600
8,382
12,334
15,179
16,286
Capital Work in Progress
1,677
2,240
839
1,303
1,899
2,196
2,800
4,110
7,317
7,993
8,508
Investments
230
901
1,253
675
1,012
966
1,952
1,588
2,069
1,000
1,127
Other Assets
2,839
3,569
3,676
4,312
4,811
5,311
7,406
8,127
13,189
16,434
17,199
Total Liabilities
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
58,797
Current Liabilities
1,555
1,666
1,678
2,141
3,039
4,008
4,210
3,828
8,511
15,359
14,334
Non Current Liabilities
1,378
2,493
2,502
2,200
2,447
3,053
5,805
7,096
21,043
15,437
16,751
Total Equity
3,443
4,300
5,214
5,649
6,707
7,383
8,508
9,470
22,489
25,275
27,713
Reserve & Surplus
3,171
3,992
4,738
4,881
5,798
6,106
7,027
7,832
17,267
19,183
21,044
Share Capital
100
100
100
300
300
600
600
600
600
600
600

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-94
300
-47
-261
210
165
72
-243
641
-380
2,004
Investing Activities
-491
-1,138
-510
-684
-703
-1,505
-3,651
-1,662
-14,260
-1,002
-203
Operating Activities
211
371
640
662
1,155
1,283
1,160
1,177
1,853
2,954
4,061
Financing Activities
186
1,068
-178
-240
-242
388
2,564
242
13,049
-2,333
-1,854

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
60.67 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
54.45 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
7.96 %
6.55 %
5.63 %
5.90 %
5.93 %
5.66 %
5.66 %
6.04 %
DIIs
6.65 %
6.89 %
6.87 %
6.83 %
7.79 %
7.30 %
7.76 %
8.63 %
11.90 %
12.56 %
14.08 %
14.51 %
13.68 %
14.30 %
14.44 %
15.37 %
15.72 %
22.82 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.89 %
11.03 %
11.49 %
11.37 %
10.87 %
10.72 %
12.07 %
12.46 %
13.21 %
13.34 %
13.61 %
14.47 %
15.53 %
14.63 %
14.57 %
14.07 %
13.63 %
12.58 %
Others
21.79 %
21.44 %
21.00 %
21.16 %
20.70 %
21.35 %
19.54 %
18.27 %
14.26 %
13.46 %
3.70 %
3.83 %
4.52 %
4.53 %
4.42 %
4.27 %
4.34 %
4.10 %
No of Share Holders
0
3,11,349
3,38,815
3,63,447
3,64,502
3,47,911
3,41,016
3,69,816
4,11,086
4,12,441
4,15,046
4,34,339
4,70,261
4,43,513
4,39,503
4,27,705
4,24,297
4,30,217

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 1 1 0.00 0.00 0.5 1.5 0.5 0.5
Dividend Yield (%) 0.00 1.01 0.33 0.37 0.00 0.00 0.25 0.57 0.15 0.14

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Jun 2019 BONUS Bonus
1:1
12 Jun 2019 271.45 257.90
01 Jul 2022 DIVIDEND Dividend
₹ 0.50 /share
30 Jun 2022 382.30 308.40
07 Jul 2023 DIVIDEND Dividend
₹ 1.50 /share
07 Jul 2023 240.45 259.50
05 Jul 2024 DIVIDEND Dividend
₹ 0.50 /share
05 Jul 2024 311.90 361.10
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 311.90 339.20
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 370.65 326.85
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Jan 2025 372.95 355.70
08 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 May 2025 339.10 346.50
04 Jul 2025 DIVIDEND Dividend
₹ 0.50 /share
04 Jul 2025 346.50 374.40
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 372.05 360.60
08 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2025 346.50 364.20

Announcements

Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The Company10 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release13 hours ago
Letters To Shareholders Under 100 Days Campaign - Saksham Niveshak4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Email Communication To Shareholders Under 100 Days Campaign - Saksham Niveshak7 days ago
Announcement under Regulation 30 (LODR)-Change in Management8 days ago
Board Meeting Outcome for Outcome Of Board Meeting8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 05, 2025
Company StatementSep 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Notification To Stock ExchangesAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Transcript Of Earnings Call Q1 FY26Aug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
ChairpersonS Speech At The 47Th Annual General Meeting Of The CompanyAug 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 07, 2025
Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Outcome Of Board Meeting - AcquisitionAug 07, 2025
Board Meeting Outcome for Financial Results For June 30 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Company StatementJul 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 17, 2025
Reg. 34 (1) Annual Report.Jul 17, 2025
47Th Annual General Meeting For Financial Year 2024-25 To Be Held On Friday August 08 2025Jul 17, 2025
Press ReleaseJul 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54 Dated May 22 2024.Jul 10, 2025
Outcome Of Board Meeting - Appointment Of Interim Company Secretary And Compliance OfficerJul 09, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Appointment Of Interim Company Secretary And Compliance OfficerJul 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 08, 2025
Board Meeting Intimation for Board Meeting Intimation To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025Jul 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 27, 2025

Technical Indicators

RSI(14)
Neutral
47.64
ATR(14)
Less Volatile
8.10
STOCH(9,6)
Neutral
60.88
STOCH RSI(14)
Neutral
74.09
MACD(12,26)
Bullish
0.84
ADX(14)
Weak Trend
14.75
UO(9)
Bearish
36.46
ROC(12)
Uptrend And Accelerating
3.40
WillR(14)
Neutral
-44.17

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Mirae Asset Large & Midcap Fund Direct-Growth
0.00%
-3998916
-0.39%
-0.35%
Nippon India Multi Cap Fund Direct-Growth
0.59%
1107616
0.02%
0.07%
ICICI Prudential Multicap Fund Direct Plan-Growth
0.66%
1000000
0.18%
0.23%
Mirae Asset Midcap Fund Direct - Growth
0.62%
-936270
-0.28%
-0.32%
Kotak Arbitrage Fund Direct-Growth
0.21%
-880000
-0.08%
0.04%
Tata Arbitrage Fund Direct - Growth
0.48%
715000
0.06%
0.18%
ICICI Prudential Equity Arbitrage Direct-Growth
0.27%
637500
0.04%
0.07%
Mirae Asset Multicap Fund Direct - Growth
0.16%
-577762
-0.59%
-0.90%
Aditya Birla Sun Life Large Cap Direct Fund-Growth
0.00%
-570423
-0.07%
-0.44%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.30%
542500
0.06%
0.15%
DSP Dynamic Asset Allocation Fund Direct-Growth
0.00%
-510000
-0.57%
-0.47%
ICICI Prudential Midcap Direct Plan-Growth
0.27%
500000
0.27%
0.27%
Invesco India Arbitrage Fund Direct-Growth
0.53%
422500
-0.03%
0.04%
Axis Arbitrage Fund Direct-Growth
0.25%
382500
0.16%
0.25%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
1.47%
354192
0.49%
1.47%
ITI Multi Cap Fund Direct - Growth
0.00%
-345782
-1.06%
0.00%
ITI Flexi Cap Fund Direct - Growth
0.00%
-334718
-1.10%
0.00%
UTI Arbitrage Fund Direct-Growth
0.46%
302500
0.04%
0.29%
Axis India Manufacturing Fund Direct-Growth
0.68%
-283322
-0.27%
0.27%
Nippon India Pharma Fund Direct-Growth
1.76%
272979
-0.01%
0.12%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.41%
-229839
-0.18%
-0.12%
Bajaj Finserv Multi Cap Fund Direct-Growth
2.35%
216544
0.61%
1.75%
Mirae Asset Arbitrage Fund Direct - Growth
0.58%
-127500
-0.21%
-0.09%
SBI Arbitrage Opportunities Fund Direct-Growth
0.11%
125000
-0.01%
0.06%
SBI Contra Direct Plan-Growth
2.15%
120012
-0.24%
0.00%

About Biocon

Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years, 11 days)
Chairperson NameKiran Mazumdar Shaw